{"transactions":[{"id":725224,"issuer":{"id":5355,"kind":"organization","name":"ARVINAS, INC."},"owners":[{"id":35090,"kind":"person","name":"Morrison Briggs","position":1,"cik":"0001654430","reported_name":"Morrison Briggs","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-26T20:22:40.000Z","date":"2026-06-24","kind":"grant","planned":false,"acquired":true,"shares":22714,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option award was granted on June 24, 2026. The shares underlying the award shall vest in full on the earlier of (i) June 24, 2027 or (ii) immediately prior to the first annual meeting of stockholders occurring after the date of grant, subject to the reporting person's continued service with the Issuer on the vesting date."}],"balance_after":22714,"derivative":{"exercise_price":8.05,"expiration_date":"2036-06-23","underlying":"Common Stock","underlying_shares":22714},"source":{"system":"sec-edgar","filing":"0001628280-26-045786","document":"wk-form4_1782505358.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1654430/000162828026045786/wk-form4_1782505358.xml","form_type":"4"}},{"id":725223,"issuer":{"id":5355,"kind":"organization","name":"ARVINAS, INC."},"owners":[{"id":35090,"kind":"person","name":"Morrison Briggs","position":1,"cik":"0001654430","reported_name":"Morrison Briggs","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-26T20:22:40.000Z","date":"2026-06-24","kind":"grant","planned":false,"acquired":true,"shares":15527,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The restricted stock units (each, an \"RSU\") were granted by the Issuer on June 24, 2026 and each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement for no consideration. The RSUs shall vest in full on the earlier of (i) June 24, 2027 or (ii) immediately prior to the first annual meeting of stockholders occurring after the date of grant,  subject to the reporting person's continued service with the Issuer on the vesting date."}],"balance_after":111548,"source":{"system":"sec-edgar","filing":"0001628280-26-045786","document":"wk-form4_1782505358.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1654430/000162828026045786/wk-form4_1782505358.xml","form_type":"4"}},{"id":744658,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":35090,"kind":"person","name":"Morrison Briggs","position":1,"cik":"0001654430","reported_name":"Morrison Briggs","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-09T21:41:28.000Z","date":"2026-06-05","kind":"grant","planned":false,"acquired":true,"shares":13000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to continued service to the Company or any of its subsidiaries, the options will vest and become exercisable in 12 equal monthly installments on the final day of each succeeding calendar month occurring after the grant date provided that the first installment vests on June 30, 2026 and the last installment vests on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2027 Annual Meeting."}],"balance_after":13000,"derivative":{"exercise_price":51.84,"expiration_date":"2036-06-05","underlying":"Common Shares","underlying_shares":13000},"source":{"system":"sec-edgar","filing":"0001193125-26-264285","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000119312526264285/ownership.xml","form_type":"4"}},{"id":853075,"issuer":{"id":5355,"kind":"organization","name":"ARVINAS, INC."},"owners":[{"id":35090,"kind":"person","name":"Morrison Briggs","position":1,"cik":"0001654430","reported_name":"Morrison Briggs","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-03-09T20:05:21.000Z","date":"2026-03-06","kind":"purchase","planned":false,"acquired":true,"shares":20000,"price":13.4035,"value":268070.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The purchase price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.364 to $13.45, inclusive. The reporting person undertakes to provide to Arvinas, Inc., any security holder of Arvinas, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote."}],"balance_after":96021,"source":{"system":"sec-edgar","filing":"0001628280-26-016003","document":"wk-form4_1773086718.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1654430/000162828026016003/wk-form4_1773086718.xml","form_type":"4"}},{"id":1032825,"issuer":{"id":5355,"kind":"organization","name":"ARVINAS, INC."},"owners":[{"id":35090,"kind":"person","name":"Morrison Briggs","position":1,"cik":"0001654430","reported_name":"Morrison Briggs","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-09-24T13:16:17.000Z","date":"2025-09-22","kind":"purchase","planned":false,"acquired":true,"shares":30000,"price":7.567,"value":227010.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The purchase price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.50 to $7.65, inclusive. The reporting person undertakes to provide to Arvinas, Inc., any security holder of Arvinas, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote."}],"balance_after":76021,"source":{"system":"sec-edgar","filing":"0001628280-25-042536","document":"wk-form4_1758719774.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1654430/000162828025042536/wk-form4_1758719774.xml","form_type":"4"}},{"id":1099895,"issuer":{"id":5355,"kind":"organization","name":"ARVINAS, INC."},"owners":[{"id":35090,"kind":"person","name":"Morrison Briggs","position":1,"cik":"0001654430","reported_name":"Morrison Briggs","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-28T01:14:34.000Z","date":"2025-06-25","kind":"grant","planned":false,"acquired":true,"shares":23105,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option award was granted on June 25, 2025. The shares underlying the award shall vest in full on the earlier of June 25, 2026 or the first meeting of the board of directors of the Issuer held after the following annual meeting of stockholders, subject to the reporting person's continued service with the Issuer on the vesting date."}],"balance_after":23105,"derivative":{"exercise_price":7.8,"expiration_date":"2035-06-24","underlying":"Common Stock","underlying_shares":23105},"source":{"system":"sec-edgar","filing":"0001655759-25-000122","document":"wk-form4_1751073270.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1654430/000165575925000122/wk-form4_1751073270.xml","form_type":"4"}},{"id":1099894,"issuer":{"id":5355,"kind":"organization","name":"ARVINAS, INC."},"owners":[{"id":35090,"kind":"person","name":"Morrison Briggs","position":1,"cik":"0001654430","reported_name":"Morrison Briggs","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-28T01:14:34.000Z","date":"2025-06-25","kind":"grant","planned":false,"acquired":true,"shares":16025,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The restricted stock units (each, an \"RSU\") were granted by the Issuer on June 25, 2025 and each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement for no consideration. The RSUs shall vest in full on the earlier of June 25, 2026 or the first meeting of the board of directors of the Issuer held after the following annual meeting of stockholders,  subject to the reporting person's continued service with the Issuer on the vesting date."}],"balance_after":46021,"source":{"system":"sec-edgar","filing":"0001655759-25-000122","document":"wk-form4_1751073270.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1654430/000165575925000122/wk-form4_1751073270.xml","form_type":"4"}},{"id":1111002,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":35090,"kind":"person","name":"Morrison Briggs","position":1,"cik":"0001654430","reported_name":"Morrison Briggs","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-13T20:10:15.000Z","date":"2025-06-12","kind":"grant","planned":false,"acquired":true,"shares":27000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on June 12, 2025. The shares underlying the option vest in full on the earlier of the first anniversary of the grant date and the next annual meeting of stockholders following the grant date, subject to the reporting person's continued service as a director."}],"balance_after":27000,"derivative":{"exercise_price":1.29,"expiration_date":"2035-06-11","underlying":"Common Stock","underlying_shares":27000},"source":{"system":"sec-edgar","filing":"0000950170-25-086173","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1654430/000095017025086173/ownership.xml","form_type":"4"}},{"id":1119666,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":35090,"kind":"person","name":"Morrison Briggs","position":1,"cik":"0001654430","reported_name":"Morrison Briggs","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-06T21:30:30.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":13000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 5, 2025 with respect to 13,000 Common Shares, with 100% of the shares vesting in 12 equal monthly installments beginning on June 30, 2025; provided that the last installment will vest on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2026 Annual General Meeting of Shareholders."}],"balance_after":13000,"derivative":{"exercise_price":38.57,"expiration_date":"2035-06-05","underlying":"Common Shares","underlying_shares":13000},"source":{"system":"sec-edgar","filing":"0000950170-25-083274","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000095017025083274/ownership.xml","form_type":"4"}},{"id":1468099,"issuer":{"id":74418,"kind":"organization","name":"Carisma Therapeutics Inc.","symbol":"CARM"},"owners":[{"id":35090,"kind":"person","name":"Morrison Briggs","position":1,"cik":"0001654430","reported_name":"Morrison Briggs","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-27T16:54:23.000Z","date":"2024-06-26","kind":"grant","planned":false,"acquired":true,"shares":19350,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option vest with respect to all of the shares underlying such option on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to the non-employee director's continued service as a director."}],"balance_after":19350,"derivative":{"exercise_price":1.22,"expiration_date":"2034-06-26","underlying":"Common Stock","underlying_shares":19350},"source":{"system":"sec-edgar","filing":"0001104659-24-075719","document":"tm2418415-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1485003/000110465924075719/tm2418415-2_4seq1.xml","form_type":"4"}},{"id":1473303,"issuer":{"id":68433,"kind":"organization","name":"Repare Therapeutics Inc.","symbol":"RPTX"},"owners":[{"id":35090,"kind":"person","name":"Morrison Briggs","position":1,"cik":"0001654430","reported_name":"Morrison Briggs","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-20T20:35:17.000Z","date":"2024-06-17","kind":"grant","planned":false,"acquired":true,"shares":27200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in equal monthly installments over twelve (12) months from the date of grant, subject to Reporting Person continuing to provide service through each such date."}],"balance_after":27200,"derivative":{"exercise_price":3.8,"expiration_date":"2034-06-16","underlying":"Common Shares","underlying_shares":27200},"source":{"system":"sec-edgar","filing":"0001415889-24-017658","document":"form4-06202024_040613.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808158/000141588924017658/form4-06202024_040613.xml","form_type":"4"}},{"id":1496296,"issuer":{"id":5355,"kind":"organization","name":"ARVINAS, INC."},"owners":[{"id":35090,"kind":"person","name":"Morrison Briggs","position":1,"cik":"0001654430","reported_name":"Morrison Briggs","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-05-31T21:51:47.000Z","date":"2024-05-29","kind":"grant","planned":false,"acquired":true,"shares":9070,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option award was granted on May 29, 2024. The shares underlying the award shall vest in full on the earlier of May 29, 2025 or the first meeting of the board of directors of the Issuer held after the following annual meeting of stockholders."}],"balance_after":9070,"derivative":{"exercise_price":33.9,"expiration_date":"2034-05-28","underlying":"Common Stock","underlying_shares":9070},"source":{"system":"sec-edgar","filing":"0001655759-24-000083","document":"wk-form4_1717192298.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1654430/000165575924000083/wk-form4_1717192298.xml","form_type":"4"}},{"id":1496295,"issuer":{"id":5355,"kind":"organization","name":"ARVINAS, INC."},"owners":[{"id":35090,"kind":"person","name":"Morrison Briggs","position":1,"cik":"0001654430","reported_name":"Morrison Briggs","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-05-31T21:51:47.000Z","date":"2024-05-29","kind":"grant","planned":false,"acquired":true,"shares":5899,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The restricted stock units (each, an \"RSU\") were granted by the Issuer on May 29, 2024 and each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement for no consideration. The RSUs shall vest in full on the earlier of May 29, 2025 or the first meeting of the board of directors of the Issuer held after the following annual meeting of stockholders."}],"balance_after":29996,"source":{"system":"sec-edgar","filing":"0001655759-24-000083","document":"wk-form4_1717192298.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1654430/000165575924000083/wk-form4_1717192298.xml","form_type":"4"}},{"id":1501501,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":35090,"kind":"person","name":"Morrison Briggs","position":1,"cik":"0001654430","reported_name":"Morrison Briggs","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-05-24T23:49:25.000Z","date":"2024-05-24","kind":"grant","planned":false,"acquired":true,"shares":17500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on May 24, 2024. The shares underlying the option vest in full on the earlier of the first anniversary of the grant date and the next annual meeting of stockholders following the grant date, subject to the reporting person's continued service as a director."}],"balance_after":17500,"derivative":{"exercise_price":4.88,"expiration_date":"2034-05-23","underlying":"Common Stock","underlying_shares":17500},"source":{"system":"sec-edgar","filing":"0000950170-24-064845","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1654430/000095017024064845/ownership.xml","form_type":"4"}},{"id":1651293,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":35090,"kind":"person","name":"Morrison Briggs","position":1,"cik":"0001654430","reported_name":"Morrison Briggs","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-02-09T21:04:08.000Z","date":"2024-02-07","kind":"grant","planned":false,"acquired":true,"shares":17000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Award of Restricted Stock Units that vests one year from the date of grant. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the earlier of a separation from service, death, disability or change in control."}],"balance_after":34836,"source":{"system":"sec-edgar","filing":"0001562180-24-001216","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218024001216/primarydocument.xml","form_type":"4"}},{"id":1810660,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":35090,"kind":"person","name":"Morrison Briggs","position":1,"cik":"0001654430","reported_name":"Morrison Briggs","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to buy)","published_at":"2023-08-10T10:50:32.000Z","date":"2023-08-09","kind":"exercise","planned":true,"acquired":false,"shares":52855,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"This option is fully vested."}],"balance_after":0,"derivative":{"exercise_price":8.77,"exercise_date":"2027-02-06","underlying":"Common Stock","underlying_shares":52855},"source":{"system":"sec-edgar","filing":"0001562180-23-006262","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218023006262/primarydocument.xml","form_type":"4"}},{"id":1810659,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":35090,"kind":"person","name":"Morrison Briggs","position":1,"cik":"0001654430","reported_name":"Morrison Briggs","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-08-10T10:50:32.000Z","date":"2023-08-09","kind":"sale","planned":true,"acquired":false,"shares":52855,"price":18.2651,"value":965401.8605,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Following the sales reported in this Form 4, the Reporting Person has a total of 559,142 options to purchase shares of common stock that are vested and immediately exercisable and a total of 247,875 options to purchase shares of common stock that have not yet vested."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sale prices ranged from $18.02 to $18.41."}],"balance_after":17836,"source":{"system":"sec-edgar","filing":"0001562180-23-006262","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218023006262/primarydocument.xml","form_type":"4"}},{"id":1810658,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":35090,"kind":"person","name":"Morrison Briggs","position":1,"cik":"0001654430","reported_name":"Morrison Briggs","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-08-10T10:50:32.000Z","date":"2023-08-09","kind":"exercise","planned":true,"acquired":true,"shares":52855,"price":8.77,"value":463538.35,"ownership":{"direct":true},"balance_after":70691,"source":{"system":"sec-edgar","filing":"0001562180-23-006262","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218023006262/primarydocument.xml","form_type":"4"}},{"id":1831496,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":35090,"kind":"person","name":"Morrison Briggs","position":1,"cik":"0001654430","reported_name":"Morrison Briggs","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to buy)","published_at":"2023-07-11T13:23:19.000Z","date":"2023-07-10","kind":"exercise","planned":true,"acquired":false,"shares":52855,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option is fully vested."}],"balance_after":0,"derivative":{"exercise_price":8.77,"expiration_date":"2027-02-06","underlying":"Common Stock","underlying_shares":52855},"source":{"system":"sec-edgar","filing":"0001562180-23-005845","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218023005845/primarydocument.xml","form_type":"4"}},{"id":1831495,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":35090,"kind":"person","name":"Morrison Briggs","position":1,"cik":"0001654430","reported_name":"Morrison Briggs","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-07-11T13:23:19.000Z","date":"2023-07-10","kind":"sale","planned":true,"acquired":false,"shares":52855,"price":20.3967,"value":1078067.5785,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Following the sales reported in this Form 4, the Reporting Person has a total of 601,143 options to purchase shares of common stock that are vested and immediately exercisable and a total of 258,729 options to purchase shares of common stock that have not yet vested."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sale prices ranged from $20.11 to $20.71."}],"balance_after":17836,"source":{"system":"sec-edgar","filing":"0001562180-23-005845","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218023005845/primarydocument.xml","form_type":"4"}},{"id":1831494,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":35090,"kind":"person","name":"Morrison Briggs","position":1,"cik":"0001654430","reported_name":"Morrison Briggs","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-07-11T13:23:19.000Z","date":"2023-07-10","kind":"exercise","planned":true,"acquired":true,"shares":52855,"price":8.77,"value":463538.35,"ownership":{"direct":true},"balance_after":70691,"source":{"system":"sec-edgar","filing":"0001562180-23-005845","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218023005845/primarydocument.xml","form_type":"4"}},{"id":1844848,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":35090,"kind":"person","name":"Morrison Briggs","position":1,"cik":"0001654430","reported_name":"Morrison Briggs","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-23T21:07:47.000Z","date":"2023-06-21","kind":"grant","planned":false,"acquired":true,"shares":13200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on June 21, 2023. The shares underlying the option vest in full on the earlier of the first anniversary of the grant date and the next annual meeting of stockholders following the grant date, subject to the reporting person's continued service as a director."}],"balance_after":13200,"derivative":{"exercise_price":2.81,"expiration_date":"2033-06-20","underlying":"Common Stock","underlying_shares":13200},"source":{"system":"sec-edgar","filing":"0000899243-23-016389","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1654430/000089924323016389/doc4.xml","form_type":"4"}},{"id":1848692,"issuer":{"id":5355,"kind":"organization","name":"ARVINAS, INC."},"owners":[{"id":35090,"kind":"person","name":"Morrison Briggs","position":1,"cik":"0001654430","reported_name":"Morrison Briggs","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-20T21:27:57.000Z","date":"2023-06-15","kind":"grant","planned":false,"acquired":true,"shares":12787,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option award was granted on June 15, 2023. The shares underlying the award shall vest in full on the earlier of June 15, 2024 or the first meeting of the board of directors of the Issuer held after the following annual meeting of stockholders."}],"balance_after":12787,"derivative":{"exercise_price":30.33,"expiration_date":"2033-06-14","underlying":"Common Stock","underlying_shares":12787},"source":{"system":"sec-edgar","filing":"0001655759-23-000065","document":"wk-form4_1687296466.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1654430/000165575923000065/wk-form4_1687296466.xml","form_type":"4"}},{"id":1848691,"issuer":{"id":5355,"kind":"organization","name":"ARVINAS, INC."},"owners":[{"id":35090,"kind":"person","name":"Morrison Briggs","position":1,"cik":"0001654430","reported_name":"Morrison Briggs","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-20T21:27:57.000Z","date":"2023-06-15","kind":"grant","planned":false,"acquired":true,"shares":4121,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The restricted stock units (each, an \"RSU\") were granted by the Issuer on June 15, 2023 and each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement for no consideration. The RSUs shall vest in full on the earlier of June 15, 2024 or the first meeting of the board of directors of the Issuer held after the following annual meeting of stockholders."}],"balance_after":24097,"source":{"system":"sec-edgar","filing":"0001655759-23-000065","document":"wk-form4_1687296466.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1654430/000165575923000065/wk-form4_1687296466.xml","form_type":"4"}},{"id":1858938,"issuer":{"id":68433,"kind":"organization","name":"Repare Therapeutics Inc.","symbol":"RPTX"},"owners":[{"id":35090,"kind":"person","name":"Morrison Briggs","position":1,"cik":"0001654430","reported_name":"Morrison Briggs","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-12T20:27:58.000Z","date":"2023-06-08","kind":"grant","planned":false,"acquired":true,"shares":27200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in equal monthly installments over twelve (12) months from the date of grant, subject to Reporting Person continuing to provide service through each such date."}],"balance_after":27200,"derivative":{"exercise_price":11.66,"expiration_date":"2033-06-07","underlying":"Common Shares","underlying_shares":27200},"source":{"system":"sec-edgar","filing":"0001209191-23-036318","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808158/000120919123036318/doc4.xml","form_type":"4"}},{"id":1860159,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":35090,"kind":"person","name":"Morrison Briggs","position":1,"cik":"0001654430","reported_name":"Morrison Briggs","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to buy)","published_at":"2023-06-09T21:32:28.000Z","date":"2023-06-09","kind":"exercise","planned":true,"acquired":false,"shares":24582,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option is fully vested."}],"balance_after":0,"derivative":{"exercise_price":6.38,"expiration_date":"2029-02-06","underlying":"Common Stock","underlying_shares":24582},"source":{"system":"sec-edgar","filing":"0001562180-23-005057","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218023005057/primarydocument.xml","form_type":"4"}},{"id":1860158,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":35090,"kind":"person","name":"Morrison Briggs","position":1,"cik":"0001654430","reported_name":"Morrison Briggs","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to buy)","published_at":"2023-06-09T21:32:28.000Z","date":"2023-06-09","kind":"exercise","planned":true,"acquired":false,"shares":28273,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option is fully vested."}],"balance_after":0,"derivative":{"exercise_price":8.77,"expiration_date":"2027-02-06","underlying":"Common Stock","underlying_shares":28273},"source":{"system":"sec-edgar","filing":"0001562180-23-005057","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218023005057/primarydocument.xml","form_type":"4"}},{"id":1860157,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":35090,"kind":"person","name":"Morrison Briggs","position":1,"cik":"0001654430","reported_name":"Morrison Briggs","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-09T21:32:28.000Z","date":"2023-06-09","kind":"sale","planned":true,"acquired":false,"shares":28273,"price":21.1791,"value":598796.6943,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Following the sales reported in this Form 4, the Reporting Person has a total of 643,144 options to purchase shares of common stock that are vested and immediately exercisable and a total of 269,583 options to purchase shares of common stock that have not yet vested."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sale prices ranged from $20.94 to $21.58."}],"balance_after":17836,"source":{"system":"sec-edgar","filing":"0001562180-23-005057","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218023005057/primarydocument.xml","form_type":"4"}},{"id":1860156,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":35090,"kind":"person","name":"Morrison Briggs","position":1,"cik":"0001654430","reported_name":"Morrison Briggs","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-09T21:32:28.000Z","date":"2023-06-09","kind":"sale","planned":true,"acquired":false,"shares":24582,"price":21.1791,"value":520624.6362,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Following the sales reported in this Form 4, the Reporting Person has a total of 643,144 options to purchase shares of common stock that are vested and immediately exercisable and a total of 269,583 options to purchase shares of common stock that have not yet vested."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sale prices ranged from $20.94 to $21.58."}],"balance_after":46109,"source":{"system":"sec-edgar","filing":"0001562180-23-005057","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218023005057/primarydocument.xml","form_type":"4"}},{"id":1860155,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":35090,"kind":"person","name":"Morrison Briggs","position":1,"cik":"0001654430","reported_name":"Morrison Briggs","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-09T21:32:28.000Z","date":"2023-06-09","kind":"exercise","planned":true,"acquired":true,"shares":28273,"price":8.77,"value":247954.21,"ownership":{"direct":true},"balance_after":70691,"source":{"system":"sec-edgar","filing":"0001562180-23-005057","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218023005057/primarydocument.xml","form_type":"4"}},{"id":1860154,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":35090,"kind":"person","name":"Morrison Briggs","position":1,"cik":"0001654430","reported_name":"Morrison Briggs","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-09T21:32:28.000Z","date":"2023-06-09","kind":"exercise","planned":true,"acquired":true,"shares":24582,"price":6.38,"value":156833.16,"ownership":{"direct":true},"balance_after":42418,"source":{"system":"sec-edgar","filing":"0001562180-23-005057","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218023005057/primarydocument.xml","form_type":"4"}},{"id":1862189,"issuer":{"id":74418,"kind":"organization","name":"Carisma Therapeutics Inc.","symbol":"CARM"},"owners":[{"id":35090,"kind":"person","name":"Morrison Briggs","position":1,"cik":"0001654430","reported_name":"Morrison Briggs","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-08T18:11:02.000Z","date":"2023-06-06","kind":"grant","planned":false,"acquired":true,"shares":38700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option vest over three years in equal monthly installments following June 6, 2023, subject to continued service to Carisma Therapeutics Inc. through the applicable vesting date."}],"balance_after":38700,"derivative":{"exercise_price":7.25,"expiration_date":"2033-06-06","underlying":"Common Stock","underlying_shares":38700},"source":{"system":"sec-edgar","filing":"0001104659-23-069492","document":"tm2318219-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1485003/000110465923069492/tm2318219-1_4seq1.xml","form_type":"4"}},{"id":1897917,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":35090,"kind":"person","name":"Morrison Briggs","position":1,"cik":"0001654430","reported_name":"Morrison Briggs","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to buy)","published_at":"2023-05-10T20:11:57.000Z","date":"2023-05-09","kind":"exercise","planned":true,"acquired":false,"shares":52855,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option is fully vested."}],"balance_after":0,"derivative":{"exercise_price":6.38,"expiration_date":"2029-02-06","underlying":"Common Stock","underlying_shares":52855},"source":{"system":"sec-edgar","filing":"0001562180-23-004032","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218023004032/primarydocument.xml","form_type":"4"}},{"id":1897916,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":35090,"kind":"person","name":"Morrison Briggs","position":1,"cik":"0001654430","reported_name":"Morrison Briggs","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-05-10T20:11:57.000Z","date":"2023-05-09","kind":"sale","planned":true,"acquired":false,"shares":52855,"price":21.4072,"value":1131477.556,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Following the sales reported in this Form 4, the Reporting Person has a total of 685,144 options to purchase shares of common stock that are vested and immediately exercisable and a total of 280,438 options to purchase shares of common stock that have not yet vested."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sale prices ranged from $20.78 to $22.99."}],"balance_after":17836,"source":{"system":"sec-edgar","filing":"0001562180-23-004032","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218023004032/primarydocument.xml","form_type":"4"}},{"id":1897915,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":35090,"kind":"person","name":"Morrison Briggs","position":1,"cik":"0001654430","reported_name":"Morrison Briggs","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-05-10T20:11:57.000Z","date":"2023-05-09","kind":"exercise","planned":true,"acquired":true,"shares":52855,"price":6.38,"value":337214.9,"ownership":{"direct":true},"balance_after":70691,"source":{"system":"sec-edgar","filing":"0001562180-23-004032","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218023004032/primarydocument.xml","form_type":"4"}},{"id":1920792,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":35090,"kind":"person","name":"Morrison Briggs","position":1,"cik":"0001654430","reported_name":"Morrison Briggs","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to buy)","published_at":"2023-04-12T20:03:51.000Z","date":"2023-04-10","kind":"exercise","planned":true,"acquired":false,"shares":52855,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option is fully vested."}],"balance_after":0,"derivative":{"exercise_price":6.38,"expiration_date":"2029-02-06","underlying":"Common Stock","underlying_shares":52855},"source":{"system":"sec-edgar","filing":"0001562180-23-003521","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218023003521/primarydocument.xml","form_type":"4"}},{"id":1920791,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":35090,"kind":"person","name":"Morrison Briggs","position":1,"cik":"0001654430","reported_name":"Morrison Briggs","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-04-12T20:03:51.000Z","date":"2023-04-10","kind":"sale","planned":true,"acquired":false,"shares":52855,"price":19.5296,"value":1032237.008,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Following the sales reported in this Form 4, the Reporting Person has a total of 727,145 options to purchase shares of common stock that are vested and immediately exercisable and a total of 291,292 options to purchase shares of common stock that have not yet vested."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sale prices ranged from $19.28 to $20.11."}],"balance_after":17836,"source":{"system":"sec-edgar","filing":"0001562180-23-003521","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218023003521/primarydocument.xml","form_type":"4"}},{"id":1920790,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":35090,"kind":"person","name":"Morrison Briggs","position":1,"cik":"0001654430","reported_name":"Morrison Briggs","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-04-12T20:03:51.000Z","date":"2023-04-10","kind":"exercise","planned":true,"acquired":true,"shares":52855,"price":6.38,"value":337214.9,"ownership":{"direct":true},"balance_after":70691,"source":{"system":"sec-edgar","filing":"0001562180-23-003521","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218023003521/primarydocument.xml","form_type":"4"}},{"id":1953769,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":35090,"kind":"person","name":"Morrison Briggs","position":1,"cik":"0001654430","reported_name":"Morrison Briggs","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Head of R&D"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-03-14T20:42:48.000Z","date":"2023-03-13","kind":"exercise","acquired":false,"shares":52854,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option is fully vested."}],"balance_after":0,"derivative":{"exercise_price":6.38,"expiration_date":"2029-02-06","underlying":"Common Stock","underlying_shares":52854},"source":{"system":"sec-edgar","filing":"0001562180-23-002770","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218023002770/primarydocument.xml","form_type":"4"}},{"id":1953768,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":35090,"kind":"person","name":"Morrison Briggs","position":1,"cik":"0001654430","reported_name":"Morrison Briggs","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Head of R&D"}}],"security":"Common Stock","published_at":"2023-03-14T20:42:48.000Z","date":"2023-03-13","kind":"sale","acquired":false,"shares":52854,"price":22.5276,"value":1190673.7704,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 822,000 options to purchase shares of common stock that are vested and immediately exercisable and a total of 302,146 options to purchase shares of common stock that have not yet vested."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sale prices ranged from $22.05 to $23.10."}],"balance_after":17836,"source":{"system":"sec-edgar","filing":"0001562180-23-002770","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218023002770/primarydocument.xml","form_type":"4"}},{"id":1953767,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":35090,"kind":"person","name":"Morrison Briggs","position":1,"cik":"0001654430","reported_name":"Morrison Briggs","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Head of R&D"}}],"security":"Common Stock","published_at":"2023-03-14T20:42:48.000Z","date":"2023-03-13","kind":"exercise","acquired":true,"shares":52854,"price":6.38,"value":337208.52,"ownership":{"direct":true},"balance_after":70690,"source":{"system":"sec-edgar","filing":"0001562180-23-002770","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218023002770/primarydocument.xml","form_type":"4"}},{"id":1960925,"issuer":{"id":74418,"kind":"organization","name":"Carisma Therapeutics Inc.","symbol":"CARM"},"owners":[{"id":35090,"kind":"person","name":"Morrison Briggs","position":1,"cik":"0001654430","reported_name":"Morrison Briggs","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-03-09T21:21:48.000Z","date":"2023-03-07","kind":"grant","acquired":true,"shares":34189,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In connection with the merger of Sesen Bio, Inc. (\"Sesen Bio\") and private company CARISMA Therapeutics Inc. (\"Carisma\"), pursuant to the Agreement and Plan of Merger and Reorganization dated as of September 20, 2022, as amended by the First Amendment thereto dated as of December 29, 2022 and the Second Amendment thereto dated as of February 13, 2023 (as amended, the \"Merger Agreement\"), which closed on March 7, 2023 (the \"Closing\"), (i) each share of Carisma common stock was converted into the right to receive 1.8994 shares of Sesen Bio common stock (the \"Exchange Ratio\") and (ii) each outstanding and unexercised option to purchase shares of Carisma common stock converted into an option to purchase shares of Sesen Bio common stock, with necessary adjustments to reflect the Exchange Ratio but otherwise the same terms and conditions."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Exchange Ratio gives effect to the 1-for-20 reverse stock split of Sesen Bio's common stock. On the Closing date, the closing price of Sesen Bio common stock was $0.6288 (unadjusted). Upon Closing, Sesen Bio was renamed \"Carisma Therapeutics Inc.\""},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares underlying this option vest over four years, with 25% of the shares vested on April 1, 2022 and the remaining shares vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service."}],"balance_after":34189,"derivative":{"exercise_price":1.46,"expiration_date":"2031-03-31","underlying":"Common Stock","underlying_shares":34189},"source":{"system":"sec-edgar","filing":"0001104659-23-030746","document":"tm238905-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1485003/000110465923030746/tm238905-1_4seq1.xml","form_type":"4"}},{"id":1960924,"issuer":{"id":74418,"kind":"organization","name":"Carisma Therapeutics Inc.","symbol":"CARM"},"owners":[{"id":35090,"kind":"person","name":"Morrison Briggs","position":1,"cik":"0001654430","reported_name":"Morrison Briggs","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-03-09T21:21:48.000Z","date":"2023-03-07","kind":"grant","acquired":true,"shares":63310,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In connection with the merger of Sesen Bio, Inc. (\"Sesen Bio\") and private company CARISMA Therapeutics Inc. (\"Carisma\"), pursuant to the Agreement and Plan of Merger and Reorganization dated as of September 20, 2022, as amended by the First Amendment thereto dated as of December 29, 2022 and the Second Amendment thereto dated as of February 13, 2023 (as amended, the \"Merger Agreement\"), which closed on March 7, 2023 (the \"Closing\"), (i) each share of Carisma common stock was converted into the right to receive 1.8994 shares of Sesen Bio common stock (the \"Exchange Ratio\") and (ii) each outstanding and unexercised option to purchase shares of Carisma common stock converted into an option to purchase shares of Sesen Bio common stock, with necessary adjustments to reflect the Exchange Ratio but otherwise the same terms and conditions."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Exchange Ratio gives effect to the 1-for-20 reverse stock split of Sesen Bio's common stock. On the Closing date, the closing price of Sesen Bio common stock was $0.6288 (unadjusted). Upon Closing, Sesen Bio was renamed \"Carisma Therapeutics Inc.\""},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying this option vest over four years, with 25% of the shares vested on July 24, 2021 and the remaining shares vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service."}],"balance_after":63310,"derivative":{"exercise_price":0.68,"expiration_date":"2030-07-23","underlying":"Common Stock","underlying_shares":63310},"source":{"system":"sec-edgar","filing":"0001104659-23-030746","document":"tm238905-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1485003/000110465923030746/tm238905-1_4seq1.xml","form_type":"4"}},{"id":1960923,"issuer":{"id":74418,"kind":"organization","name":"Carisma Therapeutics Inc.","symbol":"CARM"},"owners":[{"id":35090,"kind":"person","name":"Morrison Briggs","position":1,"cik":"0001654430","reported_name":"Morrison Briggs","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-03-09T21:21:48.000Z","date":"2023-03-07","kind":"grant","acquired":true,"shares":12175,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In connection with the merger of Sesen Bio, Inc. (\"Sesen Bio\") and private company CARISMA Therapeutics Inc. (\"Carisma\"), pursuant to the Agreement and Plan of Merger and Reorganization dated as of September 20, 2022, as amended by the First Amendment thereto dated as of December 29, 2022 and the Second Amendment thereto dated as of February 13, 2023 (as amended, the \"Merger Agreement\"), which closed on March 7, 2023 (the \"Closing\"), (i) each share of Carisma common stock was converted into the right to receive 1.8994 shares of Sesen Bio common stock (the \"Exchange Ratio\") and (ii) each outstanding and unexercised option to purchase shares of Carisma common stock converted into an option to purchase shares of Sesen Bio common stock, with necessary adjustments to reflect the Exchange Ratio but otherwise the same terms and conditions."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Exchange Ratio gives effect to the 1-for-20 reverse stock split of Sesen Bio's common stock. On the Closing date, the closing price of Sesen Bio common stock was $0.6288 (unadjusted). Upon Closing, Sesen Bio was renamed \"Carisma Therapeutics Inc.\""}],"balance_after":12175,"source":{"system":"sec-edgar","filing":"0001104659-23-030746","document":"tm238905-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1485003/000110465923030746/tm238905-1_4seq1.xml","form_type":"4"}},{"id":2026243,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":35090,"kind":"person","name":"Morrison Briggs","position":1,"cik":"0001654430","reported_name":"Morrison Briggs","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Head of R&D"}}],"security":"Stock Options (Right to buy)","published_at":"2023-02-08T21:49:08.000Z","date":"2023-02-06","kind":"exercise","acquired":false,"shares":52854,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option is fully vested."}],"balance_after":0,"derivative":{"exercise_price":6.38,"expiration_date":"2029-02-06","underlying":"Common Stock","underlying_shares":52854},"source":{"system":"sec-edgar","filing":"0001562180-23-001117","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218023001117/primarydocument.xml","form_type":"4"}},{"id":2026242,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":35090,"kind":"person","name":"Morrison Briggs","position":1,"cik":"0001654430","reported_name":"Morrison Briggs","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Head of R&D"}}],"security":"Common Stock","published_at":"2023-02-08T21:49:08.000Z","date":"2023-02-06","kind":"sale","acquired":false,"shares":52854,"price":26.8269,"value":1417908.9726,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 811,146 options to purchase shares of common stock that are vested and immediately exercisable and a total of 313,000 options to purchase shares of common stock that have not yet vested."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sale prices ranged from $26.49 to $27.91."}],"balance_after":17836,"source":{"system":"sec-edgar","filing":"0001562180-23-001117","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218023001117/primarydocument.xml","form_type":"4"}},{"id":2026241,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":35090,"kind":"person","name":"Morrison Briggs","position":1,"cik":"0001654430","reported_name":"Morrison Briggs","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Head of R&D"}}],"security":"Common Stock","published_at":"2023-02-08T21:49:08.000Z","date":"2023-02-06","kind":"exercise","acquired":true,"shares":52854,"price":6.38,"value":337208.52,"ownership":{"direct":true},"balance_after":70690,"source":{"system":"sec-edgar","filing":"0001562180-23-001117","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218023001117/primarydocument.xml","form_type":"4"}},{"id":2032322,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":35090,"kind":"person","name":"Morrison Briggs","position":1,"cik":"0001654430","reported_name":"Morrison Briggs","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Head of R&D"}}],"security":"Stock Options (Right to buy)","published_at":"2023-02-03T22:02:06.000Z","date":"2023-02-02","kind":"grant","acquired":true,"shares":32000,"price":28.55,"value":913600.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the shares subject to the option shall vest monthly over a four-year period."}],"balance_after":32000,"derivative":{"exercise_price":28.55,"expiration_date":"2033-02-02","underlying":"Common Stock","underlying_shares":32000},"source":{"system":"sec-edgar","filing":"0001562180-23-000955","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218023000955/primarydocument.xml","form_type":"4"}},{"id":2153351,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":35090,"kind":"person","name":"Morrison Briggs","position":1,"cik":"0001654430","reported_name":"Morrison Briggs","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Head of R&D"}}],"security":"Stock Options (Right to buy)","published_at":"2022-09-21T20:18:27.000Z","date":"2022-09-20","kind":"exercise","acquired":false,"shares":59649,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option is fully vested."}],"balance_after":0,"derivative":{"exercise_price":10.9,"expiration_date":"2025-09-09","underlying":"Common Stock","underlying_shares":59649},"source":{"system":"sec-edgar","filing":"0001562180-22-006788","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218022006788/primarydocument.xml","form_type":"4"}},{"id":2153350,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":35090,"kind":"person","name":"Morrison Briggs","position":1,"cik":"0001654430","reported_name":"Morrison Briggs","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Head of R&D"}}],"security":"Stock Options (Right to buy)","published_at":"2022-09-21T20:18:27.000Z","date":"2022-09-19","kind":"exercise","acquired":false,"shares":114339,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option is fully vested."}],"balance_after":0,"derivative":{"exercise_price":10.9,"expiration_date":"2025-09-09","underlying":"Common Stock","underlying_shares":114339},"source":{"system":"sec-edgar","filing":"0001562180-22-006788","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218022006788/primarydocument.xml","form_type":"4"}},{"id":2153349,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":35090,"kind":"person","name":"Morrison Briggs","position":1,"cik":"0001654430","reported_name":"Morrison Briggs","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Head of R&D"}}],"security":"Common Stock","published_at":"2022-09-21T20:18:27.000Z","date":"2022-09-20","kind":"sale","acquired":false,"shares":59649,"price":23.2529,"value":1387012.2321,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 774,958 options to purchase shares of common stock that are vested and immediately exercisable and a total of 370,042 options to purchase shares of common stock that have not yet vested."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The sale prices ranged from $22.60 to $23.75"}],"balance_after":17836,"source":{"system":"sec-edgar","filing":"0001562180-22-006788","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218022006788/primarydocument.xml","form_type":"4"}},{"id":2153348,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":35090,"kind":"person","name":"Morrison Briggs","position":1,"cik":"0001654430","reported_name":"Morrison Briggs","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Head of R&D"}}],"security":"Common Stock","published_at":"2022-09-21T20:18:27.000Z","date":"2022-09-20","kind":"exercise","acquired":true,"shares":59649,"price":10.9,"value":650174.1,"ownership":{"direct":true},"balance_after":77485,"source":{"system":"sec-edgar","filing":"0001562180-22-006788","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218022006788/primarydocument.xml","form_type":"4"}},{"id":2153347,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":35090,"kind":"person","name":"Morrison Briggs","position":1,"cik":"0001654430","reported_name":"Morrison Briggs","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Head of R&D"}}],"security":"Common Stock","published_at":"2022-09-21T20:18:27.000Z","date":"2022-09-19","kind":"sale","acquired":false,"shares":114339,"price":23.0284,"value":2633044.2276,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 774,958 options to purchase shares of common stock that are vested and immediately exercisable and a total of 370,042 options to purchase shares of common stock that have not yet vested."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sale prices ranged from $22.50 to $23.35"}],"balance_after":17836,"source":{"system":"sec-edgar","filing":"0001562180-22-006788","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218022006788/primarydocument.xml","form_type":"4"}},{"id":2153346,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":35090,"kind":"person","name":"Morrison Briggs","position":1,"cik":"0001654430","reported_name":"Morrison Briggs","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Head of R&D"}}],"security":"Common Stock","published_at":"2022-09-21T20:18:27.000Z","date":"2022-09-19","kind":"exercise","acquired":true,"shares":114339,"price":10.9,"value":1246295.1,"ownership":{"direct":true},"balance_after":132175,"source":{"system":"sec-edgar","filing":"0001562180-22-006788","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218022006788/primarydocument.xml","form_type":"4"}},{"id":2157063,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":35090,"kind":"person","name":"Morrison Briggs","position":1,"cik":"0001654430","reported_name":"Morrison Briggs","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Head of R&D"}}],"security":"Stock Options (Right to buy)","published_at":"2022-09-16T21:34:18.000Z","date":"2022-09-16","kind":"exercise","acquired":false,"shares":71966,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option is fully vested."}],"balance_after":0,"derivative":{"exercise_price":7.2,"expiration_date":"2025-06-30","underlying":"Common Stock","underlying_shares":71966},"source":{"system":"sec-edgar","filing":"0001562180-22-006706","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218022006706/primarydocument.xml","form_type":"4"}},{"id":2157062,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":35090,"kind":"person","name":"Morrison Briggs","position":1,"cik":"0001654430","reported_name":"Morrison Briggs","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Head of R&D"}}],"security":"Stock Options (Right to buy)","published_at":"2022-09-16T21:34:18.000Z","date":"2022-09-16","kind":"exercise","acquired":false,"shares":53034,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option is fully vested."}],"balance_after":0,"derivative":{"exercise_price":10.9,"expiration_date":"2025-09-09","underlying":"Common Stock","underlying_shares":53034},"source":{"system":"sec-edgar","filing":"0001562180-22-006706","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218022006706/primarydocument.xml","form_type":"4"}},{"id":2157061,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":35090,"kind":"person","name":"Morrison Briggs","position":1,"cik":"0001654430","reported_name":"Morrison Briggs","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Head of R&D"}}],"security":"Stock Options (Right to buy)","published_at":"2022-09-16T21:34:18.000Z","date":"2022-09-15","kind":"exercise","acquired":false,"shares":66775,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option is fully vested."}],"balance_after":0,"derivative":{"exercise_price":7.2,"expiration_date":"2025-06-30","underlying":"Common Stock","underlying_shares":66775},"source":{"system":"sec-edgar","filing":"0001562180-22-006706","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218022006706/primarydocument.xml","form_type":"4"}},{"id":2157060,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":35090,"kind":"person","name":"Morrison Briggs","position":1,"cik":"0001654430","reported_name":"Morrison Briggs","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Head of R&D"}}],"security":"Stock Options (Right to buy)","published_at":"2022-09-16T21:34:18.000Z","date":"2022-09-14","kind":"exercise","acquired":false,"shares":87645,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option is fully vested."}],"balance_after":0,"derivative":{"exercise_price":7.2,"expiration_date":"2025-06-30","underlying":"Common Stock","underlying_shares":87645},"source":{"system":"sec-edgar","filing":"0001562180-22-006706","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218022006706/primarydocument.xml","form_type":"4"}},{"id":2157059,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":35090,"kind":"person","name":"Morrison Briggs","position":1,"cik":"0001654430","reported_name":"Morrison Briggs","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Head of R&D"}}],"security":"Common Stock","published_at":"2022-09-16T21:34:18.000Z","date":"2022-09-16","kind":"sale","acquired":false,"shares":53034,"price":23.2195,"value":1231422.963,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 948,946 options to purchase shares of common stock that are vested and immediately exercisable and a total of 245,042 options to purchase shares of common stock that have not yet vested."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The sale prices ranged from $22.96 to $23.99"}],"balance_after":17836,"source":{"system":"sec-edgar","filing":"0001562180-22-006706","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218022006706/primarydocument.xml","form_type":"4"}},{"id":2157058,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":35090,"kind":"person","name":"Morrison Briggs","position":1,"cik":"0001654430","reported_name":"Morrison Briggs","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Head of R&D"}}],"security":"Common Stock","published_at":"2022-09-16T21:34:18.000Z","date":"2022-09-16","kind":"exercise","acquired":true,"shares":53034,"price":10.9,"value":578070.6,"ownership":{"direct":true},"balance_after":70870,"source":{"system":"sec-edgar","filing":"0001562180-22-006706","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218022006706/primarydocument.xml","form_type":"4"}},{"id":2157057,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":35090,"kind":"person","name":"Morrison Briggs","position":1,"cik":"0001654430","reported_name":"Morrison Briggs","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Head of R&D"}}],"security":"Common Stock","published_at":"2022-09-16T21:34:18.000Z","date":"2022-09-16","kind":"sale","acquired":false,"shares":71966,"price":23.2195,"value":1671014.537,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 948,946 options to purchase shares of common stock that are vested and immediately exercisable and a total of 245,042 options to purchase shares of common stock that have not yet vested."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The sale prices ranged from $22.96 to $23.99"}],"balance_after":17836,"source":{"system":"sec-edgar","filing":"0001562180-22-006706","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218022006706/primarydocument.xml","form_type":"4"}},{"id":2157056,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":35090,"kind":"person","name":"Morrison Briggs","position":1,"cik":"0001654430","reported_name":"Morrison Briggs","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Head of R&D"}}],"security":"Common Stock","published_at":"2022-09-16T21:34:18.000Z","date":"2022-09-16","kind":"exercise","acquired":true,"shares":71966,"price":7.2,"value":518155.2,"ownership":{"direct":true},"balance_after":89802,"source":{"system":"sec-edgar","filing":"0001562180-22-006706","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218022006706/primarydocument.xml","form_type":"4"}},{"id":2157055,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":35090,"kind":"person","name":"Morrison Briggs","position":1,"cik":"0001654430","reported_name":"Morrison Briggs","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Head of R&D"}}],"security":"Common Stock","published_at":"2022-09-16T21:34:18.000Z","date":"2022-09-15","kind":"sale","acquired":false,"shares":66775,"price":24.2012,"value":1616035.13,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 948,946 options to purchase shares of common stock that are vested and immediately exercisable and a total of 245,042 options to purchase shares of common stock that have not yet vested."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The sale prices ranged from $23.36 to $24.64"}],"balance_after":17836,"source":{"system":"sec-edgar","filing":"0001562180-22-006706","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218022006706/primarydocument.xml","form_type":"4"}},{"id":2157054,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":35090,"kind":"person","name":"Morrison Briggs","position":1,"cik":"0001654430","reported_name":"Morrison Briggs","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Head of R&D"}}],"security":"Common Stock","published_at":"2022-09-16T21:34:18.000Z","date":"2022-09-15","kind":"exercise","acquired":true,"shares":66775,"price":7.2,"value":480780.0,"ownership":{"direct":true},"balance_after":84611,"source":{"system":"sec-edgar","filing":"0001562180-22-006706","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218022006706/primarydocument.xml","form_type":"4"}},{"id":2157053,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":35090,"kind":"person","name":"Morrison Briggs","position":1,"cik":"0001654430","reported_name":"Morrison Briggs","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Head of R&D"}}],"security":"Common Stock","published_at":"2022-09-16T21:34:18.000Z","date":"2022-09-14","kind":"sale","acquired":false,"shares":87645,"price":23.7989,"value":2085854.5905,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 948,946 options to purchase shares of common stock that are vested and immediately exercisable and a total of 245,042 options to purchase shares of common stock that have not yet vested."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sale prices ranged from $23.36 to $24.01"}],"balance_after":17836,"source":{"system":"sec-edgar","filing":"0001562180-22-006706","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218022006706/primarydocument.xml","form_type":"4"}},{"id":2157052,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":35090,"kind":"person","name":"Morrison Briggs","position":1,"cik":"0001654430","reported_name":"Morrison Briggs","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Head of R&D"}}],"security":"Common Stock","published_at":"2022-09-16T21:34:18.000Z","date":"2022-09-14","kind":"exercise","acquired":true,"shares":87645,"price":7.2,"value":631044.0,"ownership":{"direct":true},"balance_after":105481,"source":{"system":"sec-edgar","filing":"0001562180-22-006706","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218022006706/primarydocument.xml","form_type":"4"}},{"id":2214110,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":35090,"kind":"person","name":"Morrison Briggs","position":1,"cik":"0001654430","reported_name":"Morrison Briggs","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Head of R&D"}}],"security":"Stock Options (Right to buy)","published_at":"2022-07-05T20:09:46.000Z","date":"2022-07-01","kind":"exercise","acquired":false,"shares":62292,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option is fully vested."}],"balance_after":0,"derivative":{"exercise_price":7.2,"expiration_date":"2025-06-30","underlying":"Common Stock","underlying_shares":62292},"source":{"system":"sec-edgar","filing":"0001562180-22-005475","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218022005475/primarydocument.xml","form_type":"4"}},{"id":2214109,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":35090,"kind":"person","name":"Morrison Briggs","position":1,"cik":"0001654430","reported_name":"Morrison Briggs","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Head of R&D"}}],"security":"Common Stock","published_at":"2022-07-05T20:09:46.000Z","date":"2022-07-01","kind":"sale","acquired":false,"shares":62292,"price":18.9981,"value":1183429.6452,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 1,200,616 options to purchase shares of common stock that are vested and immediately exercisable and a total of 397,792 options to purchase shares of common stock that have not yet vested."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sale prices ranged from $18.61 to $19.38"}],"balance_after":17836,"source":{"system":"sec-edgar","filing":"0001562180-22-005475","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218022005475/primarydocument.xml","form_type":"4"}},{"id":2214108,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":35090,"kind":"person","name":"Morrison Briggs","position":1,"cik":"0001654430","reported_name":"Morrison Briggs","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Head of R&D"}}],"security":"Common Stock","published_at":"2022-07-05T20:09:46.000Z","date":"2022-07-01","kind":"exercise","acquired":true,"shares":62292,"price":7.2,"value":448502.4,"ownership":{"direct":true},"balance_after":80128,"source":{"system":"sec-edgar","filing":"0001562180-22-005475","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218022005475/primarydocument.xml","form_type":"4"}},{"id":2224865,"issuer":{"id":5355,"kind":"organization","name":"ARVINAS, INC."},"owners":[{"id":35090,"kind":"person","name":"Morrison Briggs","position":1,"cik":"0001654430","reported_name":"Morrison Briggs","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-22T00:00:24.000Z","date":"2022-06-16","kind":"grant","acquired":true,"shares":10192,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option award was granted on June 16, 2022. The shares underlying the award shall vest in full on the earlier of June 16, 2023 or the first meeting of the board of directors of the Issuer held after the following annual meeting of stockholders."}],"balance_after":10192,"derivative":{"exercise_price":36.79,"expiration_date":"2032-06-15","underlying":"Common Stock","underlying_shares":10192},"source":{"system":"sec-edgar","filing":"0001209191-22-038553","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1654430/000120919122038553/doc4.xml","form_type":"4"}},{"id":2243655,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":35090,"kind":"person","name":"Morrison Briggs","position":1,"cik":"0001654430","reported_name":"Morrison Briggs","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-03T20:41:42.000Z","date":"2022-06-01","kind":"grant","acquired":true,"shares":11600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on June 1, 2022. The shares underlying the option vest in full on the earlier of the first anniversary of the grant date and the next annual meeting of stockholders following the grant date, subject to the reporting person's continued service as a director."}],"balance_after":11600,"derivative":{"exercise_price":3.43,"expiration_date":"2032-05-31","underlying":"Common Stock","underlying_shares":11600},"source":{"system":"sec-edgar","filing":"0000899243-22-020987","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1654430/000089924322020987/doc4.xml","form_type":"4"}},{"id":2270461,"issuer":{"id":68433,"kind":"organization","name":"Repare Therapeutics Inc.","symbol":"RPTX"},"owners":[{"id":35090,"kind":"person","name":"Morrison Briggs","position":1,"cik":"0001654430","reported_name":"Morrison Briggs","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-05-16T23:25:10.000Z","date":"2022-05-13","kind":"grant","acquired":true,"shares":49000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in equal monthly installments over twelve (12) months from the date of grant, subject to Reporting Person continuing to provide service through each such date."}],"balance_after":49000,"derivative":{"exercise_price":9.55,"expiration_date":"2032-05-13","underlying":"Common Shares","underlying_shares":49000},"source":{"system":"sec-edgar","filing":"0001209191-22-029362","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808158/000120919122029362/doc4.xml","form_type":"4"}},{"id":2295539,"issuer":{"id":5355,"kind":"organization","name":"ARVINAS, INC."},"owners":[{"id":35090,"kind":"person","name":"Morrison Briggs","position":1,"cik":"0001654430","reported_name":"Morrison Briggs","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-04-19T01:00:13.000Z","date":"2022-04-14","kind":"exercise","acquired":false,"shares":16188,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The exercises and sales reported on this form were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2021."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option award was granted on September 26, 2018. 1/12 of the shares underlying the award vested as of June 28, 2018, with the remainder of the shares vesting in equal quarterly installments following June 28, 2018 through March 28, 2021."}],"balance_after":494,"derivative":{"exercise_price":16,"expiration_date":"2028-09-25","underlying":"Common Stock","underlying_shares":16188},"source":{"system":"sec-edgar","filing":"0001209191-22-024674","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1654430/000120919122024674/doc4.xml","form_type":"4"}},{"id":2295538,"issuer":{"id":5355,"kind":"organization","name":"ARVINAS, INC."},"owners":[{"id":35090,"kind":"person","name":"Morrison Briggs","position":1,"cik":"0001654430","reported_name":"Morrison Briggs","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-04-19T01:00:13.000Z","date":"2022-04-14","kind":"sale","acquired":false,"shares":10754,"price":67.0344,"value":720887.9376,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The exercises and sales reported on this form were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.58 to $67.40, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within such range."}],"balance_after":19976,"source":{"system":"sec-edgar","filing":"0001209191-22-024674","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1654430/000120919122024674/doc4.xml","form_type":"4"}},{"id":2295537,"issuer":{"id":5355,"kind":"organization","name":"ARVINAS, INC."},"owners":[{"id":35090,"kind":"person","name":"Morrison Briggs","position":1,"cik":"0001654430","reported_name":"Morrison Briggs","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-04-19T01:00:13.000Z","date":"2022-04-14","kind":"sale","acquired":false,"shares":7104,"price":66.0692,"value":469355.5968,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The exercises and sales reported on this form were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.56 to $66.54, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within such range."}],"balance_after":30730,"source":{"system":"sec-edgar","filing":"0001209191-22-024674","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1654430/000120919122024674/doc4.xml","form_type":"4"}},{"id":2295536,"issuer":{"id":5355,"kind":"organization","name":"ARVINAS, INC."},"owners":[{"id":35090,"kind":"person","name":"Morrison Briggs","position":1,"cik":"0001654430","reported_name":"Morrison Briggs","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-04-19T01:00:13.000Z","date":"2022-04-14","kind":"sale","acquired":false,"shares":3102,"price":65.2393,"value":202372.3086,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The exercises and sales reported on this form were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.55 to $65.54, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of shares sold at each separate price within such range."}],"balance_after":37834,"source":{"system":"sec-edgar","filing":"0001209191-22-024674","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1654430/000120919122024674/doc4.xml","form_type":"4"}},{"id":2295535,"issuer":{"id":5355,"kind":"organization","name":"ARVINAS, INC."},"owners":[{"id":35090,"kind":"person","name":"Morrison Briggs","position":1,"cik":"0001654430","reported_name":"Morrison Briggs","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-04-19T01:00:13.000Z","date":"2022-04-14","kind":"exercise","acquired":true,"shares":16188,"price":16,"value":259008.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The exercises and sales reported on this form were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2021."}],"balance_after":40936,"source":{"system":"sec-edgar","filing":"0001209191-22-024674","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1654430/000120919122024674/doc4.xml","form_type":"4"}},{"id":2297580,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":35090,"kind":"person","name":"Morrison Briggs","position":1,"cik":"0001654430","reported_name":"Morrison Briggs","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Head of R&D"}}],"security":"Stock Options (Right to buy)","published_at":"2022-04-13T20:09:25.000Z","date":"2022-04-04","kind":"exercise","acquired":false,"shares":3128,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Reporting Person is not reporting any new transactions in this filing.\n Amendment filed to correct previously filed Form that contained an incorrect option exercise price and expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option is fully vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Reporting Person is not reporting any new transactions in this filing.\n Amendment filed to correct previously filed Form that contained an incorrect option exercise price and expiration date."}],"balance_after":0,"derivative":{"exercise_price":7.2,"expiration_date":"2025-06-30","underlying":"Common Stock","underlying_shares":3128},"source":{"system":"sec-edgar","filing":"0001562180-22-003383","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218022003383/primarydocument.xml","form_type":"4/A","original_submission_date":"2022-04-05"}},{"id":2297579,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":35090,"kind":"person","name":"Morrison Briggs","position":1,"cik":"0001654430","reported_name":"Morrison Briggs","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Head of R&D"}}],"security":"Stock Options (Right to buy)","published_at":"2022-04-13T20:09:25.000Z","date":"2022-04-01","kind":"exercise","acquired":false,"shares":70545,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Reporting Person is not reporting any new transactions in this filing.\n Amendment filed to correct previously filed Form that contained an incorrect option exercise price and expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option is fully vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Reporting Person is not reporting any new transactions in this filing.\n Amendment filed to correct previously filed Form that contained an incorrect option exercise price and expiration date."}],"balance_after":0,"derivative":{"exercise_price":7.2,"expiration_date":"2025-06-30","underlying":"Common Stock","underlying_shares":70545},"source":{"system":"sec-edgar","filing":"0001562180-22-003383","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218022003383/primarydocument.xml","form_type":"4/A","original_submission_date":"2022-04-05"}},{"id":2297578,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":35090,"kind":"person","name":"Morrison Briggs","position":1,"cik":"0001654430","reported_name":"Morrison Briggs","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Head of R&D"}}],"security":"Common Stock","published_at":"2022-04-13T20:09:25.000Z","date":"2022-04-04","kind":"exercise","acquired":true,"shares":3128,"price":7.2,"value":22521.6,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Reporting Person is not reporting any new transactions in this filing.\n Amendment filed to correct previously filed Form that contained an incorrect option exercise price and expiration date."}],"balance_after":20964,"source":{"system":"sec-edgar","filing":"0001562180-22-003383","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218022003383/primarydocument.xml","form_type":"4/A","original_submission_date":"2022-04-05"}},{"id":2297577,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":35090,"kind":"person","name":"Morrison Briggs","position":1,"cik":"0001654430","reported_name":"Morrison Briggs","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Head of R&D"}}],"security":"Common Stock","published_at":"2022-04-13T20:09:25.000Z","date":"2022-04-01","kind":"exercise","acquired":true,"shares":70545,"price":7.2,"value":507924.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Reporting Person is not reporting any new transactions in this filing.\n Amendment filed to correct previously filed Form that contained an incorrect option exercise price and expiration date."}],"balance_after":88381,"source":{"system":"sec-edgar","filing":"0001562180-22-003383","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218022003383/primarydocument.xml","form_type":"4/A","original_submission_date":"2022-04-05"}},{"id":2303704,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":35090,"kind":"person","name":"Morrison Briggs","position":1,"cik":"0001654430","reported_name":"Morrison Briggs","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Head of R&D"}}],"security":"Stock Options (Right to buy)","published_at":"2022-04-05T20:05:00.000Z","date":"2022-04-04","kind":"exercise","acquired":false,"shares":3128,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This option is fully vested."}],"balance_after":0,"derivative":{"exercise_price":10.9,"expiration_date":"2025-09-09","underlying":"Common Stock","underlying_shares":3128},"source":{"system":"sec-edgar","filing":"0001562180-22-003223","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218022003223/primarydocument.xml","form_type":"4"}},{"id":2303703,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":35090,"kind":"person","name":"Morrison Briggs","position":1,"cik":"0001654430","reported_name":"Morrison Briggs","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Head of R&D"}}],"security":"Stock Options (Right to buy)","published_at":"2022-04-05T20:05:00.000Z","date":"2022-04-01","kind":"exercise","acquired":false,"shares":70545,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This option is fully vested."}],"balance_after":0,"derivative":{"exercise_price":10.9,"expiration_date":"2025-09-09","underlying":"Common Stock","underlying_shares":70545},"source":{"system":"sec-edgar","filing":"0001562180-22-003223","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218022003223/primarydocument.xml","form_type":"4"}},{"id":2303702,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":35090,"kind":"person","name":"Morrison Briggs","position":1,"cik":"0001654430","reported_name":"Morrison Briggs","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Head of R&D"}}],"security":"Common Stock","published_at":"2022-04-05T20:05:00.000Z","date":"2022-04-04","kind":"sale","acquired":false,"shares":3128,"price":18.2928,"value":57219.8784,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 1,221,283 options to purchase shares of common stock that are vested and immediately exercisable and a total of 439,417 options to purchase shares of common stock that have not yet vested."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The sale prices ranged from $17.75 to $19.17."}],"balance_after":17836,"source":{"system":"sec-edgar","filing":"0001562180-22-003223","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218022003223/primarydocument.xml","form_type":"4"}},{"id":2303701,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":35090,"kind":"person","name":"Morrison Briggs","position":1,"cik":"0001654430","reported_name":"Morrison Briggs","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Head of R&D"}}],"security":"Common Stock","published_at":"2022-04-05T20:05:00.000Z","date":"2022-04-04","kind":"exercise","acquired":true,"shares":3128,"price":10.9,"value":34095.2,"ownership":{"direct":true},"balance_after":20964,"source":{"system":"sec-edgar","filing":"0001562180-22-003223","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218022003223/primarydocument.xml","form_type":"4"}},{"id":2303700,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":35090,"kind":"person","name":"Morrison Briggs","position":1,"cik":"0001654430","reported_name":"Morrison Briggs","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Head of R&D"}}],"security":"Common Stock","published_at":"2022-04-05T20:05:00.000Z","date":"2022-04-01","kind":"sale","acquired":false,"shares":70545,"price":17.4579,"value":1231567.5555,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 1,221,283 options to purchase shares of common stock that are vested and immediately exercisable and a total of 439,417 options to purchase shares of common stock that have not yet vested."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The sale prices ranged from $17.18 to $17.69."}],"balance_after":17836,"source":{"system":"sec-edgar","filing":"0001562180-22-003223","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218022003223/primarydocument.xml","form_type":"4"}},{"id":2303699,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":35090,"kind":"person","name":"Morrison Briggs","position":1,"cik":"0001654430","reported_name":"Morrison Briggs","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Head of R&D"}}],"security":"Common Stock","published_at":"2022-04-05T20:05:00.000Z","date":"2022-04-01","kind":"exercise","acquired":true,"shares":70545,"price":10.9,"value":768940.5,"ownership":{"direct":true},"balance_after":88381,"source":{"system":"sec-edgar","filing":"0001562180-22-003223","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218022003223/primarydocument.xml","form_type":"4"}},{"id":2303698,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":35090,"kind":"person","name":"Morrison Briggs","position":1,"cik":"0001654430","reported_name":"Morrison Briggs","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Head of R&D"}}],"security":"Common Stock","published_at":"2022-04-05T20:05:00.000Z","date":"2022-04-01","kind":"sale","acquired":false,"shares":24500,"price":17.4414,"value":427314.3,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 1,221,283 options to purchase shares of common stock that are vested and immediately exercisable and a total of 439,417 options to purchase shares of common stock that have not yet vested."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The sale prices ranged from $17.19 to $17.66."}],"balance_after":17836,"source":{"system":"sec-edgar","filing":"0001562180-22-003223","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218022003223/primarydocument.xml","form_type":"4"}},{"id":2303697,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":35090,"kind":"person","name":"Morrison Briggs","position":1,"cik":"0001654430","reported_name":"Morrison Briggs","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Head of R&D"}}],"security":"Common Stock","published_at":"2022-04-05T20:05:00.000Z","date":"2022-04-01","kind":"sale","acquired":false,"shares":6000,"price":17.4389,"value":104633.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 1,221,283 options to purchase shares of common stock that are vested and immediately exercisable and a total of 439,417 options to purchase shares of common stock that have not yet vested."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sale prices ranged from $17.21 to $17.62."}],"balance_after":42336,"source":{"system":"sec-edgar","filing":"0001562180-22-003223","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218022003223/primarydocument.xml","form_type":"4"}},{"id":2413099,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":35090,"kind":"person","name":"Morrison Briggs","position":1,"cik":"0001654430","reported_name":"Morrison Briggs","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Head of R&D"}}],"security":"Stock Options (Right to buy)","published_at":"2022-02-03T22:32:43.000Z","date":"2022-02-02","kind":"grant","acquired":true,"shares":160000,"price":15.79,"value":2526400.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The securities awarded on 02/02/2022 were in the form of stock options issued pursuant to the Syndax Pharmaceuticals, Inc. 2015 Omnibus Incentive Plan. Options to purchase 100,000 shares of common stock shall vest in 48 successive equal monthly installments measured from 02/02/2022. Options to purchase 60,000 shares of common stock shall vest periodically upon the Issuer achieving certain milestones."}],"balance_after":160000,"derivative":{"exercise_price":15.79,"expiration_date":"2032-02-02","underlying":"Common Stock","underlying_shares":160000},"source":{"system":"sec-edgar","filing":"0001562180-22-001080","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218022001080/primarydocument.xml","form_type":"4"}},{"id":2431785,"issuer":{"id":5355,"kind":"organization","name":"ARVINAS, INC."},"owners":[{"id":35090,"kind":"person","name":"Morrison Briggs","position":1,"cik":"0001654430","reported_name":"Morrison Briggs","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-01-20T02:00:12.000Z","date":"2022-01-14","kind":"exercise","acquired":false,"shares":16188,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The exercises and sales reported on this form were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2021."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This option award was granted on September 26, 2018. 1/12 of the shares underlying the award vested as of June 28, 2018, with the remainder of the shares vesting in equal quarterly installments following June 28, 207 through March 28, 2021."}],"balance_after":16682,"derivative":{"exercise_price":16,"expiration_date":"2028-09-25","underlying":"Common Stock","underlying_shares":16188},"source":{"system":"sec-edgar","filing":"0000899243-22-002557","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1654430/000089924322002557/doc4.xml","form_type":"4"}},{"id":2431784,"issuer":{"id":5355,"kind":"organization","name":"ARVINAS, INC."},"owners":[{"id":35090,"kind":"person","name":"Morrison Briggs","position":1,"cik":"0001654430","reported_name":"Morrison Briggs","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-01-20T02:00:12.000Z","date":"2022-01-14","kind":"sale","acquired":false,"shares":2108,"price":67.6927,"value":142696.2116,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The exercises and sales reported on this form were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.5400 to $67.9600, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer or the Staff of the SEC, upon request, the number of shares sold at each separate price within the range set forth in this footnote (5)."}],"balance_after":24748,"source":{"system":"sec-edgar","filing":"0000899243-22-002557","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1654430/000089924322002557/doc4.xml","form_type":"4"}},{"id":2431783,"issuer":{"id":5355,"kind":"organization","name":"ARVINAS, INC."},"owners":[{"id":35090,"kind":"person","name":"Morrison Briggs","position":1,"cik":"0001654430","reported_name":"Morrison Briggs","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-01-20T02:00:12.000Z","date":"2022-01-14","kind":"sale","acquired":false,"shares":5100,"price":67.2831,"value":343143.81,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The exercises and sales reported on this form were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.5300 to $67.5200, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the SEC, upon request, the number of shares sold at each separate price within the range set forth in this footnote (4)."}],"balance_after":26856,"source":{"system":"sec-edgar","filing":"0000899243-22-002557","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1654430/000089924322002557/doc4.xml","form_type":"4"}},{"id":2431782,"issuer":{"id":5355,"kind":"organization","name":"ARVINAS, INC."},"owners":[{"id":35090,"kind":"person","name":"Morrison Briggs","position":1,"cik":"0001654430","reported_name":"Morrison Briggs","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-01-20T02:00:12.000Z","date":"2022-01-14","kind":"sale","acquired":false,"shares":3833,"price":65.2417,"value":250071.4361,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The exercises and sales reported on this form were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.9200 to $65.8900, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the SEC, upon request, the number of shares sold at each separate price within the range set forth in this footnote (3)."}],"balance_after":31956,"source":{"system":"sec-edgar","filing":"0000899243-22-002557","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1654430/000089924322002557/doc4.xml","form_type":"4"}},{"id":2431781,"issuer":{"id":5355,"kind":"organization","name":"ARVINAS, INC."},"owners":[{"id":35090,"kind":"person","name":"Morrison Briggs","position":1,"cik":"0001654430","reported_name":"Morrison Briggs","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-01-20T02:00:12.000Z","date":"2022-01-14","kind":"sale","acquired":false,"shares":9919,"price":64.332,"value":638109.108,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The exercises and sales reported on this form were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.9000 to $64.8800, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2)."}],"balance_after":35789,"source":{"system":"sec-edgar","filing":"0000899243-22-002557","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1654430/000089924322002557/doc4.xml","form_type":"4"}},{"id":2431780,"issuer":{"id":5355,"kind":"organization","name":"ARVINAS, INC."},"owners":[{"id":35090,"kind":"person","name":"Morrison Briggs","position":1,"cik":"0001654430","reported_name":"Morrison Briggs","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-01-20T02:00:12.000Z","date":"2022-01-14","kind":"exercise","acquired":true,"shares":16188,"price":16,"value":259008.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The exercises and sales reported on this form were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2021."}],"balance_after":45708,"source":{"system":"sec-edgar","filing":"0000899243-22-002557","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1654430/000089924322002557/doc4.xml","form_type":"4"}},{"id":2463596,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":35090,"kind":"person","name":"Morrison Briggs","position":1,"cik":"0001654430","reported_name":"Morrison Briggs","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Options (Right to buy)","published_at":"2021-12-20T23:44:51.000Z","date":"2021-12-17","kind":"exercise","acquired":false,"shares":35156,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option is fully vested."}],"balance_after":0,"derivative":{"exercise_price":10.9,"expiration_date":"2025-09-09","underlying":"Common Stock","underlying_shares":35156},"source":{"system":"sec-edgar","filing":"0001562180-21-007810","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218021007810/primarydocument.xml","form_type":"4"}},{"id":2463595,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":35090,"kind":"person","name":"Morrison Briggs","position":1,"cik":"0001654430","reported_name":"Morrison Briggs","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-12-20T23:44:51.000Z","date":"2021-12-17","kind":"sale","acquired":false,"shares":35156,"price":20,"value":703120.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 1,305,602 options to purchase shares of common stock that are vested and immediately exercisable and a total of 339,083 options to purchase shares of common stock that have not yet vested."}],"balance_after":48336,"source":{"system":"sec-edgar","filing":"0001562180-21-007810","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218021007810/primarydocument.xml","form_type":"4"}},{"id":2463594,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":35090,"kind":"person","name":"Morrison Briggs","position":1,"cik":"0001654430","reported_name":"Morrison Briggs","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-12-20T23:44:51.000Z","date":"2021-12-17","kind":"exercise","acquired":true,"shares":35156,"price":10.9,"value":383200.4,"ownership":{"direct":true},"balance_after":83492,"source":{"system":"sec-edgar","filing":"0001562180-21-007810","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218021007810/primarydocument.xml","form_type":"4"}},{"id":2562849,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":35090,"kind":"person","name":"Morrison Briggs","position":1,"cik":"0001654430","reported_name":"Morrison Briggs","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Options (Right to buy)","published_at":"2021-09-21T20:35:03.000Z","date":"2021-09-20","kind":"exercise","acquired":false,"shares":50,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option is fully vested."}],"balance_after":0,"derivative":{"exercise_price":7.2,"expiration_date":"2025-06-30","underlying":"Common Stock","underlying_shares":50},"source":{"system":"sec-edgar","filing":"0001562180-21-006038","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218021006038/primarydocument.xml","form_type":"4"}}],"next_cursor":"2021-09-21T20:35:03.000000Z,2562849"}